I tend to stay away from technical, preclinical science here at MMB. Focusing on therapies that are doing well in human studies is one thing. But lab studies in a test tube or mice? A bit abstract for me--and I'm guessing many of you, too. But I think this research is different. Let me introduce
I will be hosting this month's Myeloma Cure Panel webcast tomorrow evening at 6 PM Eastern time. The broadcast will focus on questions you have about how best to withstand the seemingly endless assault of multiple myeloma--and myeloma therapy--on our quality of life. Cure Talk sponsors these broadcasts. Click-on the headline link below to read
Yesterday we heard from Jim Bond in his own words, written last summer. Today I would like to help fill-in some of the blanks as I continue to introduce my inspirational friend. To recap; Jim managed to live with myeloma ten years until a near crisis nearly ended his life. This is where it gets
I first heard Jim Bond's myeloma story four years ago. I met Jim and his wonderful wife, Kathleen, in Cambridge, Massachusetts. We had volunteered to help Millennium Pharmaceuticals start a patient advisory board. As we got to know each other in-between meetings, I learned that Jim was a sixteen year survivor, from Shaker Heights, Ohio,
One of Andrew Schorr's better clips featuring Dr. Craig Hofmeister, Ohio State University Comprehensive Cancer Center, and Dr. Sagar Lonial, Winship Cancer Institute of Emory University, discussing different myeloma therapies including stem cell transplants, non-transplants, targeted and combination therapies: Transplant or Targeted Therapy: What's the Mainstay for Treatment in Multiple Myeloma?
Today I would like to pass-along a reader question, along with an update from John Knighten out in Seattle, who was preparing for this week's first of two back-to-back stem cell transplants. Let's start with Sara from North Carolina. Sara has a question about Revlimid and possible liver damage: Hi Pat, Just wondering if you've
Today I would like to give a shout-out to my good friend and the inspiration for my 4th book, Richard "Radar" Blustein. Richard checked-in to Moffitt Cancer Center February 11th to undergo his first stem cell transplant. While I was merrily celebrating my birthday, Richard was having a catheter surgically implanted in his chest so
It's official: I have kicked my daily Diet Coke habit. Why bother--especially since I was only drinking one or two cans a day? Haven't you been paying attention? Remember this post from a month ago: Convincing evidence that drinking soda isn’t good for myeloma patients IMF Medical Director, Dr. Brian Durie, came-out forcefully against
Some of you might already know March is multiple myeloma awareness month. But I noticed this week that a number of media outlets aren't waiting to run stories about our cancer. But before I begin my report, I was excited to see Dr. Sergio Giralt, BMT and myeloma specialist at Memorial Sloan-Kettering cancer center, featured
How do I feel today? That depends on what you mean by "feel." By feel do you mean my energy or pain levels? How about emotionally? Dropping Revlimid from my chemo regimen (still on weekly Velcade and 20 mg dex) has jump-started my numbers. All my blood counts are back to normal and my energy
Today Nick break's Total Therapy (TT) down into distinct segements; induction, transplants, consolidation and maintenance. Total Therapy Demystified (Part Two) Multiple myeloma survivor and Total Therapy Patient Nick van Dyk PHASE ONE: INDUCTION In traditional conservative treatment approaches, induction refers to the use of one or more agents to reduce disease burden before a transplant.
For someone that isn't a doctor, I know a lot about myeloma therapies. Not so much about the science of how they work, but the timing of it all--when best to use them and ways to help minimize side effects. But I still have a lot to learn about one specific treatment philosophy: Total Therapy.
Yesterday I promised that "I will post a brief beginner’s primer tomorrow that should be quite helpful to newly diagnosed myeloma patients, their families and caregivers." So here goes... I started by updating the dedicated section I have on our site for newly diagnosed patients. You will find it at the top of the page
Our good friend and nutritional columnist, Danny Parker, is excited about a new study released last week in the Journal of the American Society of Hematology: Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Danny is considered a high risk patient, so I understand why this comprehensive study
Better enjoy that box of chocolates now! British researchers have linked how high sugar levels raise cancer risks. Interesting how I found this news by way of India. Not exactly the type of thing the U.S. sugar lobby would like to lead-out around Valentine's Day! Scientists decode how high sugar levels raise cancer risk The
Here is Part Two of Mark's early myeloma journey as told by his 28 year old daughter, Stephanie: Patient Snapshot: Mark from Ohio (Part Two) Honestly, I can remember all the way back to October of the prior year, where he (Mark) was having problems walking, because of a bone spur, which I can't help
Thank you for all of your awesome comments, emails and facebook birthday greetings yesterday! Late last night I wrote this before heading to bed: So many great friends! The bond between fellow myeloma survivors, their families and caregivers can be amazing! When my head hits the pillow 10 minutes from now, I will rest easy
Birthdays and anniversaries help all of us mark the passing of time, and myeloma survivors are no exception. But those of us battling multiple myeloma have our own unique set of dates to remember: the day we were diagnosed, the day we achieved our first remission and for many of us our stem cell transplant
Nancy, one of MMB's most faithful readers, wanted to pass-along the sad news that a pioneer of the Canadian myeloma community, Carol Westberg, passed away recently. I never met Carol, but I did exchange emails with her from time to time. She was always helpful and upbeat. I'm sure she will be missed! In Memoriam:
The internet is flooded with excitement following the FDA's limited approval of celgene's newest IMiD, pomalidomide (trade name, POMALYST). POM is an analogue of thalidomide (trade name, Thalomid). Researchers actually developed POM before Revlimid, but sat on it for a decade--choosing to intensify clinical study activity recently, culminating in yesterday's FDA approval. I'm going to